A microvessel-on-a-chip, jointly developed and optimized by Philip Morris International (PMI) and organ-on-a-chip specialists MIMETAS (Leiden, The Netherlands), used to detect early onset of atherogenesis.
The microvessel-on-a-chip can be used under flow to measure the attachment of immune cells to the blood vessel wall—an important feature of early onset atherogenesis—as well as gain unique mechanistic insights through analysis of transcriptomic profiles. In addition, the model has been shown to be effective in applications such as the toxicological assessment of consumer products.
“The microvessel-on-a-chip has been developed in line with 21st Century Toxicology and the drive to limit animal testing through the development of new physiologically relevant in vitro models,” said Dr. Carine Poussin, PMI.
“While rodent models are commonly used to investigate the mechanisms of atherogenesis, we have now demonstrated the suitability of an alternative in vitro model in a real-world setting. The scalability of the microvessel-on-a-chip offers the potential to further develop the model for a range of mechanistic investigations of vascular diseases. This has important implications for a number of fields, including toxicological assessment, drug discovery, and precision medicine.”
Not only does the microvessel-on-a-chip have the potential to reduce the need for animal testing in line with the 3Rs principle (replace, reduce, and refine the use of animals in research),3 it may also provide more accurate, detailed, and timely data.
By using human tissues, organ-on-a-chip models avoid the challenges involved in translating the results observed in one species to another.
In association with advances in molecular endpoint assessment and computational modelling, they can also help decrease the rate of clinical failure of new drugs and be used as a valuable tool for selection of precision medicine solutions. [APBN]